Navigation Links
PharmaNet's Bioanalytical Laboratory Recognized by the Standards Council of Canada for Good Laboratory Practice Compliance
Date:6/28/2011

PRINCETON, N.J., June 28, 2011 /PRNewswire/ -- PharmaNet Development Group, Inc., a leading provider of drug development services to the pharmaceutical, biotechnology, generic drug and medical device industries, announced today that its bioanalytical laboratory in Quebec City, Canada, has received formal recognition from the Standards Council of Canada (SCC) for its compliance with the Organization for Economic Co-operation and Development (OECD) Principles of Good Laboratory Practice (GLP).

"After an in-depth review by a four-person inspection team, the Standards Council of Canada awarded us with official recognition of GLP compliance, acknowledging the premier level of quality and compliance maintained in our laboratory," said Tony Jones, Executive Director, Quality Assurance and Compliance.

Mr. Jones continued, "We have a long track record of successful inspections from global regulatory bodies, including a re-certification from Brazil's ANVISA just prior to the SCC inspection. This OECD GLP recognition consolidates our position as the partner of choice for companies seeking assured international registration of their products."

The final guidance describing the program was announced by Health Canada in April 2010. Thirty-four countries in North America, Europe and Asia constitute the OECD, an inter-governmental organization that pursues, among many other policies, the international harmonization of test methods and good laboratory practices. Upholding the principles of GLP ensures that a laboratory's quality system and management controls are consistent and reliable, which is essential for producing high quality and valid test data.

PharmaNet's laboratories offer complete bioanalytical services for small and large molecules across the continuum of drug development. The company's other laboratory in Princeton, NJ, is also GLP-compliant. Together the labs offer an extensive method development and validation services, with more than 1000 validated assays and rapid sample handling capabilities.

About PharmaNet

PharmaNet Development Group, Inc., a recognized leader of global drug development services to the pharmaceutical, biotechnology, generic drug, and medical device industries, provides comprehensive capabilities in Phase I-IV clinical development, bioanalytical and bioequivalence services, regulatory, staffing, and therapeutic solutions. For the applied knowledge and intelligent solutions needed to accelerate drug development programs of all sizes around the world, PharmaNet works for you. For more information, please visit www.PharmaNet.com.

Contact: Anne-Marie Hess
Phone:   (609) 951-6842
E-mail:   ahess@pharmanet.com


'/>"/>
SOURCE PharmaNet Development Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cetero Research Names Dr. Roger Hayes President of Bioanalytical Operations
2. QPS Expands Phase 1 and Bioanalytical Capability by Acquisition of Bioserve, India
3. MicroConstants Completes Installation of Latest LC/MS/MS Technology to Achieve Improved Sensitivity in Bioanalytical Method Development
4. PharmaNet Experts to Showcase Bioanalytical Posters at ASMS 2011
5. Instrumentation Laboratory Receives FDA Clearance for HemosIL RecombiPlasTin 2G Assay
6. BD and PEPFAR Collaborate to Strengthen Laboratory Systems in Fight Against HIV/AIDS and TB
7. Focus Diagnostics Launches Laboratory Test for Chikungunya Virus
8. Eating Walnuts Slows Cancer Growth, Laboratory Study Finds
9. J. Craig Venter, Ph.D. Receives Double Helix Medal from Cold Spring Harbor Laboratory
10. Gene Therapy Corrects Sickle Cell Disease in Laboratory Study
11. deCODE Receives California Clinical Laboratory License
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... , Feb. 11, 2016 The primary goal ... future adoption patterns on the usage of liquid biopsy. ... following: - Timeframe of liquid biopsy adoption ... cfDNA and Evs—by organization type - Sample inflow to ... blood, saliva, stool, serum, and so on. - Correlation ...
(Date:2/11/2016)... PRO-DEX, INC. (NasdaqCM: PDEX) today announced financial results for its ... also filed its Quarterly Report on Form 10-Q for the ... Exchange Commission today. --> --> ... --> Net sales for the three months ... $5.4 million from $2.8 million for the three months ended ...
(Date:2/11/2016)... 2016  Kindred Biosciences, Inc. (NASDAQ: KIN ), ... lives of pets, today announced the submission to FDA ... Drug Application (NADA) for Zimeta™ (dipyrone injection, KIND-012).  Positive ... Zimeta for the control of pyrexia (fever) in horses ... --> --> The Chemistry, Manufacturing, and ...
Breaking Medicine Technology:
(Date:2/12/2016)... ... 12, 2016 , ... Miami Dental Specialists is excited to bring patients the ... Beginning in January, Miami Dental Specialists will offer the non-metal implants as a safe, ... to be chosen by the dental implant manufacturer, Straumann, to bring this cutting-edge technology ...
(Date:2/12/2016)... ... February 12, 2016 , ... J Thomas & ... continuing it’s commitment to act as Agents of Change in the community, announces ... area homeless families to fulfill immediate needs and help them move into permanent ...
(Date:2/12/2016)... ... February 12, 2016 , ... Nearly every health website ... health. These articles generally list between five and 15 foods that should be ... every one of these lists and believes that nutritious eye healthy foods are ...
(Date:2/12/2016)... ... February 12, 2016 , ... Homeowners now have a next ... North America’s leading brand of building products, has improved upon its industry-best array ... mobile version of the ColorView® Exterior Style and Color Selector. Created expressly for ...
(Date:2/12/2016)... Colo. (PRWEB) , ... February 12, 2016 , ... A ... the past 35 years. A president has access to health and wellness resources most ... the free world, no single individual has a schedule as frenetic as the U.S. ...
Breaking Medicine News(10 mins):